Is Pfizer Stock Set To See Higher Levels Post Q3 Results?

+2.59%
Upside
27.89
Market
28.61
Trefis
PFE: Pfizer logo
PFE
Pfizer

Pfizer (NYSE: PFE) is scheduled to report its Q3 2021 results on Tuesday, November 2. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Covid-19 vaccine. Pfizer should see an overall pickup in pharmaceutical demand due to an increase in hospital visits with economies opening up gradually. We expect the company to navigate well based on these trends over the latest quarter. Furthermore, we also think PFE stock remains attractive at the current valuation. Trefis’ forecast indicates that Pfizer’s valuation is $52 per share, which is 18% above the current market price of $44. Our interactive dashboard analysis on Pfizer’s Pre-Earnings has additional details.

(1) Revenues expected to be above the consensus estimates

Trefis estimates Pfizer’s Q3 2021 revenues to be around $23.5 billion, 4% above the $22.6 billion consensus estimate. Now that the economies are opening up with vaccination programs underway in multiple countries, pharmaceutical companies will likely benefit from an increase in the volume of new patient starts. For Pfizer, its Covid-19 vaccine remains the key growth driver in the near term, with 2021 annual sales projected to be as high as $35 billion, per Trefis estimates.

Relevant Articles
  1. Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
  2. Should You Pick Pfizer Stock At $30?
  3. Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
  4. Will Pfizer Stock See Higher Levels Post Q1 Earnings?
  5. Is Pfizer Stock Undervalued At $40?
  6. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock

Pfizer’s Q2 2021 sales were up 86% y-o-y to $19.0 billion, primarily driven by $7.8 billion sales from its Covid-19 vaccine, and the contribution of this vaccine is expected to remain high in Q3. Overall, it appears that the Covid-19 vaccine will continue to drive the company’s top and bottom line expansion for now, but leaving that aside, revenue for its other drugs grew 10% in Q2, led by strong growth in biosimilars and alliance revenues, a trend expected to continue in the near term. Our dashboard on Pfizer Revenues offers more details on the company’s segments.

2) EPS likely to be above the consensus estimates

Pfizer’s Q3 2021 adjusted earnings per share (EPS) is expected to be $1.35 per Trefis analysis, compared to the consensus estimate of $1.08. Pfizer’s adjusted net income of $6.1 billion in Q2 2021 reflected a large 75% rise from its $3.5 billion figure in the prior-year quarter, primarily due to higher revenues. For the full year 2021, we expect the adjusted EPS to be higher at $4.65 compared to $2.22 in 2020.

(3) Stock price estimate 18% above the current market price

Going by our Pfizer’s Valuation, with an EPS estimate of $4.65 and a P/E multiple of 11x in 2021, this translates into a price of $52, over 18% higher than the current market price of $44. While the 11x figure is lower than the levels of over 14x seen in 2018 and 16x as recently as late 2020, this can be attributed to the fact that Pfizer’s EPS will be very high in 2021, followed by a decline from 2022 onward, with a slowdown in Covid-19 vaccine sales. Look at our Covid-19 Vaccine Updates for more details.

Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year.

While PFE stock looks attractive at its current levels, 2020 has created many pricing discontinuities which can also offer trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Mettler vs Abbott.

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since 2016.

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates